Thank you for your post @RAN58
What are your thoughts on PAA now being the lowest valued Phase II Oncology company on the ASX?
Our nearest comparative is $100m MC for an Oncology company IPO last year that have just completed Phase I.
Any insight would be welcomed on why you believe PAA is valued at only $30m?
As you know I'm across 18 to 23 Biotechs at any one time ,, I believe in the Science of MPL for reference ,, I am becoming concerned at the lengthy timeframes and lack of clear communication... especially the timeframe on the Leiden Data 10 months? Before Christmas was the first timeframe ,, now 10 months in surely must impact PAA timeline ,, or there was some serious redundancy added.....
I'm looking at attending the AGM this year and look forward to meeting with you.. NZT
Top Twenty 30 June 2021 with variations, page-4
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
0.005(2.63%) |
Mkt cap ! $94.89M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 20.0¢ | 19.5¢ | $32.56K | 166.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 291431 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 96525 | 2 |
View Market Depth
| Last trade - 10.44am 09/10/2024 (20 minute delay) ? |
| PAA (ASX) Chart |